

June 17, 2026



# VolitionRx Announces Collaboration with Sysmex

HENDERSON, Nev., June 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex ([TYO: 6869](#)), a leader in global *in vitro* diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.

**Gael Forterre**, Chief Commercial Officer, Volition commented:

"We are proud to have entered into this agreement with Sysmex, as we implement our strategy to out license our proprietary Nu.Q® NETs test to large companies with a worldwide presence, to leverage their knowledge of specific diseases, product development, regulatory experience and their installed base of proprietary analyzers. Sysmex is a global leader in the field of *in vitro* diagnostics for hemostasis and thrombosis, among other diseases, where Neutrophil Extracellular Traps ("NETS") play such an important role.

"Following the successful transfer of our Nu.Q® NETs assay onto Sysmex's platform we are delighted to commence the optimization phase in diseases associated with NETosis. NETosis is implicated in a wide range of diseases, including sepsis and other acute and chronic diseases.

"We believe that Volition's Nu.Q® NETs test could provide not only improved diagnostic information to aid clinical decision-making and personalized care, but could also be a low-cost test to continue to monitor a patient's condition.

"The commercial opportunity for the Nu.Q® NETs assay is significant, with a Total Addressable Market of \$3.8 billion<sup>[1]</sup>.

"It is exciting to progress the collaboration with Sysmex and we look forward to a fruitful long-term partnership together."

<sup>[1]</sup> Data on File, Volition TAM Model

## About Sysmex

Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in *in vitro* diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal

desire of people to live longer and healthier lives. For more information about Sysmex, please visit [www.sysmex.co.jp/en/](http://www.sysmex.co.jp/en/).

## **About Volition**

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

**Media Enquiries:** Louise Batchelor, Volition, [mediarelations@volition.com](mailto:mediarelations@volition.com) +44 (0)7557 774620

## **Safe Harbor Statement**

Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might

develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "\$" refer to the legal currency of the United States of America.

View original content: <https://www.prnewswire.com/news-releases/volitionrx-announces-collaboration-with-sysmex-302803026.html>

SOURCE VolitionRx Limited